Cargando…
MiR-454-3p Promotes Oxaliplatin Resistance by Targeting PTEN in Colorectal Cancer
Colorectal cancer is one of the most common malignancies worldwide. Oxaliplatin is the first-line chemotherapeutic agent for the treatment of advanced colorectal cancer. However, acquired resistance to oxaliplatin limits its therapeutic efficacy, and the underlying mechanism remains largely unclear....
Autores principales: | Qian, Xiao-Lan, Zhou, Fang, Xu, Song, Jiang, Jian, Chen, Zhi-Peng, Wang, Shao-Kai, Zuo, Yun, Ni, Chen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8129568/ https://www.ncbi.nlm.nih.gov/pubmed/34017681 http://dx.doi.org/10.3389/fonc.2021.638537 |
Ejemplares similares
-
Identification of Target PTEN-Based miR-425 and miR-576 as Potential Diagnostic and Immunotherapeutic Biomarkers of Colorectal Cancer With Liver Metastasis
por: Hu, Xiaoyun, et al.
Publicado: (2021) -
miR-454 promotes survival and induces oxaliplatin resistance in gastric carcinoma cells by targeting CYLD
por: Huang, Chaoqun, et al.
Publicado: (2020) -
MiR-140 leads to MRE11 downregulation and ameliorates oxaliplatin treatment and therapy response in colorectal cancer patients
por: Horak, Josef, et al.
Publicado: (2022) -
Dichloroacetate Overcomes Oxaliplatin Chemoresistance in Colorectal Cancer through the miR-543/PTEN/Akt/mTOR Pathway
por: Liang, Yu, et al.
Publicado: (2019) -
Inhibition of miR-19a partially reversed the resistance of colorectal cancer to oxaliplatin via PTEN/PI3K/AKT pathway
por: Zhang, Ye, et al.
Publicado: (2020)